| P2093 | author name string | Shelbi C Jim On | |
| | Joshua Zeichner | |
| P2860 | cites work | Isotretinoin and psychopathology: a review | Q21203918 |
| | Isotretinoin-Induced Inflammatory Bowel Disease in an Adolescent | Q22241558 |
| | Isotretinoin use and the risk of inflammatory bowel disease: a case-control study | Q24621195 |
| | 13-cis-retinoic acid suppresses hippocampal cell division and hippocampal-dependent learning in mice | Q24625727 |
| | The use of isotretinoin in acne | Q24630660 |
| | Sensitivity, specificity, and positive predictive value of multiple malformations in isotretinoin embryopathy surveillance | Q28332628 |
| | Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data | Q30591549 |
| | Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests? | Q30712478 |
| | Multimodal treatment of acne, acne scars and pigmentation | Q33511893 |
| | Diet and acne: a review of the evidence | Q34016843 |
| | An analysis of reports of depression and suicide in patients treated with isotretinoin | Q34092291 |
| | Systemic retinoid therapy | Q34129801 |
| | Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010. | Q34159991 |
| | Isotretinoin use and subsequent depression and suicide: presenting the evidence | Q34206918 |
| | Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. | Q34209858 |
| | Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study | Q34300022 |
| | The complete genome sequence of Propionibacterium acnes, a commensal of human skin | Q34337656 |
| | Prolonged Remissions of Cystic and Conglobate Acne with 13-cis-Retinoic Acid | Q34345683 |
| | Suicide, depression, and isotretinoin: is there a causal link? | Q34405234 |
| | 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes | Q34507245 |
| | Inflammatory events are involved in acne lesion initiation | Q34535060 |
| | Isotretinoin--unapproved indications/uses and dosage: a physician's reference | Q34541429 |
| | Functional brain imaging alterations in acne patients treated with isotretinoin | Q34557207 |
| | Profile of acne patients in the Philippines requiring a second course of oral isotretinoin | Q34564145 |
| | Low-dose isotretinoin in the treatment of acne vulgaris | Q34565771 |
| | Oral treatment with ACCUTANE does not increase measures of anhedonia or depression in rats | Q34583704 |
| | Isotretinoin therapy and the incidence of acne relapse: a nested case-control study | Q34584358 |
| | Retinoic acid embryopathy | Q34686260 |
| | Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. | Q52872243 |
| | Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? | Q52872552 |
| | Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. | Q53449369 |
| | The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. | Q53587730 |
| | Acne vulgaris | Q54139548 |
| | Acne treatment and inflammatory bowel disease: what is the evidence? | Q54561093 |
| | Isotretinoin therapy is associated with early skeletal radiographic changes. | Q55062671 |
| | A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin | Q57076463 |
| | Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore | Q34727109 |
| | Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment | Q34729115 |
| | Roaccutane treatment guidelines: results of an international survey | Q34742462 |
| | Acne vulgaris in the elderly: the response to low-dose isotretinoin | Q34753822 |
| | A causal association between isotretinoin and inflammatory bowel disease has yet to be established. | Q35006726 |
| | Acne in infancy and acne genetics | Q35059487 |
| | Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. | Q36170034 |
| | Insights in the pathogenic potential of Propionibacterium acnes from its complete genome | Q36224764 |
| | Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients | Q36733948 |
| | Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. | Q36813049 |
| | RAR and RXR modulation in cancer and metabolic disease | Q36956230 |
| | Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. | Q37056825 |
| | Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin | Q37825507 |
| | Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? | Q38046622 |
| | High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study | Q40646360 |
| | High albumin levels restrict the kinetics of 13-cis retinoic acid uptake and intracellular isomerization to all-trans retinoic acid and inhibit its anti-proliferative effect on SZ95 sebocytes | Q40712559 |
| | 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors | Q40860130 |
| | Current use and future potential role of retinoids in dermatology | Q40903040 |
| | Neurobehavioral teratology of isotretinoin | Q40910134 |
| | Descriptive epidemiology of acne vulgaris in the community | Q41592104 |
| | Does oral isotretinoin prevent Propionibacterium acnes resistance? | Q41601893 |
| | Oral isotretinoin. How can we treat difficult acne patients? | Q41601909 |
| | Chemoprevention of Skin Cancer in Xeroderma Pigmentosum | Q42450262 |
| | Depression--a side effect of 13-cis-retinoic acid therapy | Q42584522 |
| | Chronic oral treatment with 13-cis-retinoic acid (isotretinoin) or all-trans-retinoic acid does not alter depression-like behaviors in rats | Q42662935 |
| | Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin | Q42680672 |
| | What is the cumulative effect of long-term, low-dose isotretinoin on the development of DISH? | Q43548639 |
| | A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne | Q43682192 |
| | Incidence of depression related to isotretinoin treatment in 100 acne vulgaris patients | Q44021194 |
| | Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne | Q45137387 |
| | An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients | Q45741414 |
| | Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. | Q45923603 |
| | A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. | Q45973971 |
| | iPLEDGE allegiance to the pill: evaluation of year 1 of a birth defect prevention and monitoring system | Q46107861 |
| | Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris | Q46163258 |
| | Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents | Q46173668 |
| | Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris | Q46293444 |
| | Creatine phosphokinase values during isotretinoin treatment for acne | Q46673601 |
| | Low dose isotretinoin combined with tretinoin is effective to correct abnormalities of acne | Q46799451 |
| | Retinoic acid amplifies the host immune response to LPS through increased T lymphocytes number and LPS binding protein expression | Q46821810 |
| | High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life | Q48398468 |
| | Impaired locomotion and dopamine signaling in retinoid receptor mutant mice | Q48525361 |
| | Effects of isotretinoin on obsessive compulsive symptoms, depression, and anxiety in patients with acne vulgaris | Q48617508 |
| | Food increases the bioavailability of isotretinoin. | Q51645377 |
| | Early skeletal hyperostoses secondary to 13-cis-retinoic acid. | Q52274829 |
| | Pharmacokinetics of isotretinoin following a single oral dose. | Q52717735 |
| P433 | issue | 5 | |
| P304 | page(s) | 377-389 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Dermatologic Therapy | Q15766374 |
| P1476 | title | Isotretinoin updates | |
| P478 | volume | 26 | |